Skip to main content
Caplight Logo









Nosis Bio

Nosis Bio

Private
Berkeley, CaliforniaHealthcare & Life Scienceshttps://www.nosisbio.com/

Last Round

Grant

Jul 18, 2023

Total Funding Raised

$13M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Nosis Bio is a biotechnology company that develops a drug delivery platform using artificial intelligence to create cell-targeted RNA medicines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

RNA therapeuticsdrug discovery platformAI drug discoverycell-targeted deliverygene silencinggenerative AIbiotech platformin vivo validationphysics-aware AIprecision medicinein silico drug designdrug deliverybiotech R&DAI-native biotechligand design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nosis Bio Comparables

Compare Nosis Bio with similar companies based on industry and business-model similarity.

Nosis Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gensaic
84%
Bonito Biosciences
83%
Vivatides Therapeutics
81%

Nosis Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 18, 2023
SeedMar 1, 2023

Key People

Founding team and executive leadership

Seth Myers

Co-Founder CTO

Founding Team

Jim Martineau

Co-Founder & CEO

Founding Team

Nosis Bio Investors

Notable investors and investment history

Nosis Bio investors
InvestorRounds
AlleyCorpSeed
Cystic Fibrosis FoundationSeed, Grant
Madrona Venture GroupSeed
Sahsen VenturesSeed
KdT VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 28, 2026

    Grew 26% QoQ, from 19 to 24 employees.

  • Aug 21, 2026

    Monthly visitors grew 80% MoM, from 1.6K to 2.9K.

Nosis Bio Filings

Explore SEC and related filing metadata, where available.

Nosis Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nosis Bio's valuation, stock price, and market status.

Is Nosis Bio a public or private company?

Nosis Bio is a private company.

What is the current stock price of Nosis Bio?

Nosis Bio is a private company with no public stock price. Caplight tracks Nosis Bio's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Nosis Bio worth (valuation)?

Valuation information for Nosis Bio is not publicly available.

Can I buy Nosis Bio stock?

Nosis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nosis Bio's last funding round?

Nosis Bio's most recent funding round was Grant on July 18, 2023.

Who are the main investors in Nosis Bio?

Key investors in Nosis Bio include AlleyCorp, Cystic Fibrosis Foundation, Madrona Venture Group, Sahsen Ventures, KdT Ventures.

Will Nosis Bio IPO soon?

No public IPO plans have been announced for Nosis Bio.

How can I track Nosis Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nosis Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBerkeley, California
Employee Range18
Year Founded2021
Last FundingJul 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?